Dexpramipexole

Phase 2Small molecule

KKnopp Biosciences

Dexpramipexole is one of 69 small molecule programs targeting Sinusitis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

SinusitisActive, not recruiting

AsthmaActive, not recruiting

Hypereosinophilic SyndromeActive, not recruiting

SinusitisPhase 2

Active, not recruiting

AsthmaPhase 2

Active, not recruiting

Hypereosinophilic SyndromePhase 2

Active, not recruiting

Competition

Competitive Landscape

1050 competitors in Asthma

#DrugCompanyPhaseTrials

Veramyst

GSK

Preclinical

46 2

Spiriva

Boehringer Ingelheim

Preclinical

8 3

Qvar

Chiesi Farmaceutici S.p.A.

Preclinical

8 4

Dexpramipexole

KKnopp Biosciences

Phase 2

1 5

Formoterol Fumarate

AstraZeneca

Preclinical

8 6

Atrovent

Boehringer Ingelheim

Preclinical

2 7

Blood Withdrawn

Emergent BioSolutions

Preclinical

1 8

Ozone

TTanta University

Preclinical

1 9

Spiriva

Boehringer Ingelheim

Preclinical

3 10

Allergen Immunotherapy Extract

JJohns Hopkins University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

IPEX5 trials

Dexpramipexole Renal PK Study

Completed·KKnopp Biosciences·Phase 1·NCT01424176·36 enrolled

Dexpramipexole SAD/MAD Study

Completed·KKnopp Biosciences·Phase 1·NCT01449578·63 enrolled

Phase 3 Extension Study of Dexpramipexole in ALS

Terminated·KKnopp Biosciences·Phase 3·NCT01622088·616 enrolled

Show 2 more trials

Study in Healthy Volunteers of the Bioavailability of Dexpramipexole Tablets and Food Effects

Completed·KKnopp Biosciences·Phase 1·NCT01607034·24 enrolled

Phase 3 Study of Dexpramipexole in ALS

Completed·KKnopp Biosciences·Phase 3·NCT01281189·942 enrolled

Interaction2 trials

Dexpramipexole and Cimetidine Drug Drug Interaction (DDI)

Completed·KKnopp Biosciences·Phase 1·NCT01536249·14 enrolled

Dexpramipexole and Warfarin Drug Drug Interaction (DDI) Study

Completed·KKnopp Biosciences·Phase 1·NCT01597310·15 enrolled

Hypereosinophilic syndrome1 trial

Study to Evaluate Safety and Efficacy of Dexpramipexole (KNS-760704) in Subjects With Hypereosinophilic Syndrome

Unknown status·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT02101138·15 enrolled

Asthma1 trial

Dexpramipexole Dose-Ranging Biomarker Study in Subjects With Eosinophilic Asthma

Completed·KKnopp Biosciences·Phase 2·NCT04046939·534 enrolled

Sinusitis1 trial

Study of Dexpramipexole Chronic Sinusitis With Nasal Polyps and Eosinophilia

Completed·KKnopp Biosciences·Phase 2·NCT02217332·20 enrolled

1 more indication

Heart1 trial

Study to Evaluate the QTC Interval in Healthy Volunteers Dosed With Dexpramipexole (QTC = Electrocardiogram (ECG) Interval Measured From the Onset of the QRS Complex to the End of the T Wave Corrected for Heart Rate)

Completed·KKnopp Biosciences·Phase 1·NCT01511029·68 enrolled

Sources

References

[1]
ClinicalTrials.gov — 11 trial records for Dexpramipexole. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Dexpramipexole compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Dexpramipexole. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Knopp Biosciences company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: KKnopp Biosciences

Dexpramipexole

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

IPEX5 trials

Interaction2 trials

Hypereosinophilic syndrome1 trial

Asthma1 trial

Sinusitis1 trial

Heart1 trial

References

Drug Info

Quick Facts

Related News